FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released on ...

And so this motion will really be about how we can support businesses, especially the SMEs in this green transition.” The upcoming motion – which will be tabled some time in 2025 – aims to ...

Government dropped appeal of verdict that voided patents Critics warn pact’s precedent risks public health innovation Public health advocates expressed outrage at the US government’s settlement of its ...

The latest trading session saw Gilead Sciences (GILD) ending at $92.96, denoting a +1.22% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other Billionaire Steve Cohen’s top stock picks. Steve Cohen is one of the most prominent ...

Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January 16th.

Green Day's long-awaited South African debut on Jan. 19 was anything but ordinary. By Jessica Lynch Green Day delivered a politically charged performance during their Jan. 19 concert at ...

GS-1427 is under clinical development by Gilead Sciences and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 45% phase transition ...